Keystone Financial Planning Inc. Acquires 221,853 Shares of GSK plc (NYSE:GSK)

Keystone Financial Planning Inc. boosted its holdings in GSK plc (NYSE:GSK - Free Report) by 3,660.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 227,913 shares of the pharmaceutical company's stock after buying an additional 221,853 shares during the quarter. GSK makes up approximately 2.4% of Keystone Financial Planning Inc.'s investment portfolio, making the stock its 9th largest position. Keystone Financial Planning Inc.'s holdings in GSK were worth $7,708,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in GSK. Eastern Bank acquired a new stake in shares of GSK in the third quarter valued at about $26,000. ST Germain D J Co. Inc. boosted its holdings in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock valued at $27,000 after acquiring an additional 522 shares during the last quarter. Sunbelt Securities Inc. increased its position in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after purchasing an additional 302 shares during the period. Concord Wealth Partners raised its holdings in GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company's stock worth $32,000 after purchasing an additional 547 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new position in shares of GSK in the 2nd quarter worth approximately $37,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Down 1.1 %

Shares of GSK stock traded down $0.38 on Monday, reaching $32.71. 4,673,691 shares of the company were exchanged, compared to its average volume of 3,213,227. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The company has a 50-day moving average of $34.30 and a 200-day moving average of $38.12. The company has a market cap of $67.79 billion, a price-to-earnings ratio of 21.24, a PEG ratio of 1.52 and a beta of 0.63. GSK plc has a one year low of $32.55 and a one year high of $45.92.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were issued a $0.3928 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 annualized dividend and a yield of 4.80%. This is a positive change from GSK's previous quarterly dividend of $0.38. GSK's dividend payout ratio is presently 95.45%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on GSK. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Monday. Guggenheim downgraded GSK from a "buy" rating to a "neutral" rating in a report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft downgraded GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Finally, Jefferies Financial Group cut GSK from a "buy" rating to a "hold" rating and decreased their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.